Janux Therapeutics Appoints Dr. Zachariah McIver as Chief Medical Officer to Advance Cancer Therapies

Janux Therapeutics Elevates Leadership with Appointment of Dr. Zachariah McIver as Chief Medical Officer

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering immunotherapies, takes a significant step forward with the promotion of Dr. Zachariah McIver to Chief Medical Officer. This strategic appointment is expected to enhance the company’s clinical development initiatives, particularly for its prostate-specific membrane antigen (PSMA) TRACTr candidate, JANX007. Dr. McIver's extensive background in T cell engagers, combined with his leadership experience, positions him to make a substantial impact on Janux's efforts to advance innovative therapies for cancer treatment.

Dr. McIver brings over 20 years of clinical research expertise to his new role, having previously served as Executive Medical Director at Amgen. There, he successfully led cross-functional teams in the formulation of clinical study strategies for bispecific T-cell engagers aimed at various malignancies. His academic credentials are impressive; he holds a B.S. in Physics and General Sciences from the University of Oregon, a Doctorate in Osteopathic Medicine from Ohio University, and a Ph.D. in Molecular Medicine from Wake Forest University. Furthermore, Dr. McIver completed his residency at the Cleveland Clinic and a fellowship in hematology and oncology at the National Institutes of Health, showcasing a robust foundation in both clinical and research settings.

Under Dr. McIver's leadership, Janux aims to capitalize on its TRACTr platform, which has successfully produced its first clinical candidate, JANX007, currently undergoing Phase 1 trials for metastatic castration-resistant prostate cancer (mCRPC). The company is also advancing other candidates, including JANX008, which targets epidermal growth factor receptor (EGFR) and is being evaluated for various solid tumors such as colorectal carcinoma and triple-negative breast cancer. Janux continues to prioritize its preclinical pipeline, actively developing further TRACTr and TRACIr programs, which are designed to enhance the efficacy and safety of cancer treatments.

In addition to Dr. McIver's promotion, Janux is making strides in its clinical trials, with both JANX007 and JANX008 currently in Phase 1 studies. These trials represent a critical step in the company's goal to deliver innovative immunotherapies that could significantly improve patient outcomes. As Janux Therapeutics enhances its leadership and continues to advance its clinical pipeline, the company remains committed to its mission of transforming cancer treatment through cutting-edge science and technology.